Plus therapeutics to present data from two studies supporting the treatment of leptomeningeal metastases with rhenium-186 nanoliposome

Austin, texas, aug. 11, 2021 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult to treat cancers, today announced it will present data from one planned clinical trial and one completed preclinical study evaluating its lead investigational drug, rhenium-186 nanoliposome (186rnl), for the treatment of leptomeningeal metastases (lm). the data will be presented at the third annual conference on brain metastases hosted by the society for neuro-oncology (sno), being held virtually august 19-20, 2021.
PSTV Ratings Summary
PSTV Quant Ranking